Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 2 for:    intrathecal trastuzumab
Previous Study | Return to List | Next Study

Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Northwestern University
Sponsor:
Information provided by (Responsible Party):
Northwestern University
ClinicalTrials.gov Identifier:
NCT01325207
First received: March 7, 2011
Last updated: October 15, 2014
Last verified: October 2014
  Purpose

The drug being studied is Trastuzumab, a medicine that is used to slow or stop the growth of cancerous tumors that are HER-2 positive. Patients are being asked to participate in this study because they have been diagnosed with having tumor cells in their spinal fluid. This study will investigate the safety and effects of this drug when given directly into the spinal fluid.

Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer The purpose of this research study is to determine a safe dose of the drug Trastuzumab and then determine how effective this treatment is.


Condition Intervention Phase
Breast Cancer
Radiation: Trastuzumab
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer

Resource links provided by NLM:


Further study details as provided by Northwestern University:

Primary Outcome Measures:
  • Determine the safety and maximum tolerated dose of IT trastuzumab. [ Time Frame: treated twice a week for 4 weeks, then once a week for 4 weeks, and then every 2 weeks ] [ Designated as safety issue: No ]
    The initial phase of this study will be a dose escalation trial of 3-6 patients per each dose level. Dose escalation will occur until the MTD or the maximal defined dose (MDD) (40 mg) is reached. The starting dose will be 10 mg for cohort 1, 20 mg for cohort 2, 30 mg for cohort 3 and 40 mg for cohort 4. Patients will be treated twice a week for 4 weeks, then once a week for 4 weeks, and then every 2 weeks. The starting dose is based on the safety of this dose and higher doses as reported in the literature. The MTD or MDD will be used for phase II.


Secondary Outcome Measures:
  • Determine response to IT trastuzumab: radiological, cytological and clinical. [ Time Frame: A baseline enhanced MRI of the brain and spine within 14 days of registration. The first follow up MRI of the brain and spine will be done after 4 weeks then every 6-8 weeks +/- 3 days for each ] [ Designated as safety issue: No ]

    A baseline MRI of the brain and spine within 14 days of registration. Follow up MRI of the brain and spine,at 4 weeks then every 6-8 weeks.

    CT chest/abdomen/pelvis is optional but will be ordered if needed to assess systemic disease and any response.


  • Define the CSF PK of IT trastuzumab. [ Time Frame: CSF analysis for cytology will be done every 2 weeks when CSF is obtained for PK and then every 4 weeks ] [ Designated as safety issue: No ]
    Patients may need a CSF flow study at the discretion of the treating principal investigator. If a spinal block is seen by CSF flow study or MRI, it will need local RT prior to treatment. Concurrent radiation is not allowed.


Estimated Enrollment: 24
Study Start Date: April 2011
Estimated Study Completion Date: March 2017
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: intravenous trastuzumab infusions
A Phase I single dose study (H0407g) of intravenous trastuzumab infusions ranging from 10-500 mg resulted in dose-dependent pharmacokinetics (PK) with serum clearance of trastuzumab decreasing with an increasing dose at doses <250 mg. PK modeling of trastuzumab concentration-time data from 7 patients that were administered doses of 250 mg and 500 mg had in a mean halflife of 5.8 days (range 1-32 days).
Radiation: Trastuzumab
Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and then every 2 weeks
Other Names:
  • (also known as Herceptin, which
  • is a medicine that is used to slow or stop the growth of a cancerous tumor)

Detailed Description:

Phase I: Patients will be treated in cohorts of 3-6 based on standard phase I dose escalation parameters requiring 0/3 or 1/6 patients per cohort to have a DLT before dose escalation. Dosing is as follows: Cohort 1-10 mg IT, cohort 2-20 mg IT, cohort 3-30 mg IT and cohort 4-40 mg IT. Patients will be treated twice a week for 4 weeks, then once a week for 4 weeks, and then every 2 weeks. Toxicity for DLT will be assessed during first 4 weeks of treatment. Phase II: Patients will be treated with the MTD or maximal defined dose. Patients will be treated twice a week for 4 weeks, then once a week for 4 weeks, and then every 2 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

ELIGIBILITY CRITERIA

  • HER2 positive (IHC 3+ and/or FISH positive) breast cancer patients with leptomeningeal metastases by MRI or CSF (if MRI is negative).

    o Review will be performed for cases not reviewed at Northwestern for confirmation, but will not preclude patients from entering the trial (pathology report is sufficient for registration).

  • Patients can have concomitant brain metastases as long as they do not require active treatment or have been treated.
  • Patients with leptomeningeal disease from ependymomas, gliomas, and medulloblastoma will be eligible for phase I
  • Life expectancy > 8 weeks
  • Normal renal (creatinine < 1.5 ULN), liver (bilirubin < 1.5 x ULN, transaminases < 3.0 x ULN, except in known hepatic metastasis, wherein may be < 5 x ULN) and blood counts (WBC > 3.0, Neutrophils > 1500, platelets >100 000, Hemoglobin > 10).
  • LVEF > 50%
  • KPS > 50
  • Age > 18 years
  • Cannot be on systemic agents (chemotherapy) that have CNS penetration unless they develop leptomeningeal metastases while on these agent(s) and have controlled systemic disease. May continue on IV trastuzumab, lapatinib or hormonal agents if controlling systemic disease and developed LM while on therapy. Patients requiring systemic chemotherapy are eligible but will not be able to start treatment until after the first assessment by imaging and cytology.
  • Patients may need a CSF flow study at the discretion of the treating principal investigator. If a spinal block is seen by CSF flow study or MRI, it will need local RT prior to treatment. Concurrent radiation is not allowed.
  • Patients should be > 2 weeks from RT treatment and all effects of treatment should have resolved
  • No limit on prior systemic or IT therapies.
  • CSF sampling to document LM if not documented on MRI.
  • Must be willing to have an Ommaya reservoir placed.
  • NO history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix) unless in complete remission and off all therapy for the disease for a minimum of 3 years.
  • Significant medical or psychiatric illness that would interfere with compliance and ability to tolerate treatment as outlined in the protocol.
  • Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study.
  • Women may not be pregnant or breast-feeding.
  • Ability to sign an informed consent; can be signed by family member or health care proxy. Informed consent must be done prior to registration on study.
  • All patients must have given signed, informed consent prior to registration on study.
  • No known hypersensitivity to trial medications Note: The eligibility criteria listed above are interpreted literally and cannot be waived.

Exclusion Criteria:

- Any deviations from the inclusion criteria

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01325207

Contacts
Contact: Jeffrey Raizer, MD 312-695-0990 Jraizer@nmff.org
Contact: Study Coordinator 312-695-1301 cancertrials@northwestern.edu

Locations
United States, California
University of California San Francisco (UCSF) Recruiting
San Francisco, California, United States, 94143-1710
Contact: Michelle Melisko, MD    415-353-7070      
Principal Investigator: Michelle Melisko, MD         
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Nancy Lin, MD       nancy_lin@dfci.harvard.edu   
Principal Investigator: Nancy Lin, MD         
United States, New York
Memorial Sloan-Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Elena Pentsova, MD    212-639-7330    PentsovE@mskcc.org   
Principal Investigator: Elena Pentsova, MD         
United States, Rhode Island
Rhode Island Hospital Active, not recruiting
Providence, Rhode Island, United States, 02903
United States, Texas
Texas Oncology-Austin Recruiting
Austin, Texas, United States, 78705
Contact: Morris Groves, MD    512-421-4100      
Principal Investigator: Morris D. Groves, M.D.         
Sponsors and Collaborators
Northwestern University
Investigators
Principal Investigator: Jeffrey Raizer, MD Northwestern University
  More Information

No publications provided

Responsible Party: Northwestern University
ClinicalTrials.gov Identifier: NCT01325207     History of Changes
Other Study ID Numbers: NU 10C03, STU00040150
Study First Received: March 7, 2011
Last Updated: October 15, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Northwestern University:
Breast Cancer

Additional relevant MeSH terms:
Trastuzumab
Breast Neoplasms
Meningeal Carcinomatosis
Breast Diseases
Central Nervous System Neoplasms
Meningeal Neoplasms
Neoplasms
Neoplasms by Site
Nervous System Diseases
Nervous System Neoplasms
Skin Diseases
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014